Smad7 Cancer Research Results

Smad7, Smad7: Click to Expand ⟱
Source:
Type:
Smad7 is not a cell line but a protein—a member of the Smad family—that acts as an inhibitory regulator within the transforming growth factor-beta (TGF-β) signaling pathway.
Smad7 is expressed widely across tissues and its expression is often upregulated in response to TGF-β stimulation, forming an auto-inhibitory loop.

In some cancers, Smad7 is upregulated. This upregulation may help cancer cells bypass the growth-inhibitory effects of TGF-β signaling during early tumorigenesis, effectively blocking TGF-β's tumor suppressor role.
• Conversely, in other cancer contexts, lower Smad7 levels might contribute to a more active TGF-β pathway, which in later stages can promote tumor invasion and metastasis. Thus, the role of Smad7 might shift depending on disease progression.
• In many cases, the TGF-β signaling pathway acts as a double-edged sword in cancer: initially suppressing tumor growth but later facilitating processes like epithelial-to-mesenchymal transition (EMT), immune evasion, and metastasis. Smad7 is one of the key modulators in tipping this balance, so its expression levels will vary accordingly.

In summary, while Smad7 is commonly upregulated in certain cancer cells to counteract TGF-β’s suppressor function during early tumorigenesis, its overall role and expression level can vary depending on the specific cancer type and stage.
Scientific Papers found: Click to Expand⟱
1097- AG,    Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin
- in-vitro, Nor, HMrSV5 - in-vivo, NA, NA
*EMT↓,
*E-cadherin↑,
*α-SMA↓,
*Vim↓,
*β-catenin/ZEB1↓, rat
*Smad7↑, Astragalus down-regulated β-catenin by enhancing Smad7 expression.

1257- PI,    Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways
- ex-vivo, LiverDam, NA
*Fibronectin↓,
*α-SMA↓,
*COL1↓, collagen1a
*COL3A1↓,
*TGF-β↓,
*EMT↓,
*MMP2↓, PL produced a significant attenuation of the BDL-induced increase in MMP-2, α-SMA, collagen1a, and collagen3a expressio
*α-SMA↓,
*Smad7↑, Smad7 protein expression was decreased in BDL mice whereas upon PL treatment, it increased significantly
*E-cadherin↑, oral administration of PL demonstrated a dose-dependent increase in expression of E-cadherin and reduction in vimentin and fibronectin expression
*Vim↓,
*hepatoP↑, Our study displays that PL treatment is capable of restoring liver enzymes, suggesting a hepatoprotective potential of PL in liver injury markers
*antiOx↑, PL showed powerful antioxidant effects by attenuating oxidative-nitrosative stress and increasing intracellular antioxidant GSH levels in BDL liver.
*GSH↑,
*ROS↓,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSH↑, 1,   ROS↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,  

Migration ⓘ

COL1↓, 1,   COL3A1↓, 1,   E-cadherin↑, 2,   Fibronectin↓, 1,   MMP2↓, 1,   Smad7↑, 2,   TGF-β↓, 1,   Vim↓, 2,   α-SMA↓, 3,   β-catenin/ZEB1↓, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,  
Total Targets: 15

Scientific Paper Hit Count for: Smad7, Smad7
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:999  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page